Zevra Therapeutics (ZVRA) announced that the Company has executed an exclusive expanded access distribution agreement with Uniphar. The agreement enables Niemann-Pick Disease Type C patients to access MIPLYFFA, for reimbursed named patient supply in select territories outside of Europe.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA: